On May 29, 2018 Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ: EGRX) reported that management will present at two investor conferences in June as follows (Press release, Eagle Pharmaceuticals, MAY 29, 2018, View Source [SID1234527072]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference:

Jefferies 2018 Global Healthcare Conference

Date: Thursday, June 7, 2018
Time: 1:30 p.m. Eastern Daylight Time
Location: Grand Hyatt New York, NYC
Presenters:

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer

Conference:

William Blair 38th Annual Growth Stock Conference

Date: Tuesday, June 12, 2018
Time: 3:30 p.m. Central Daylight Time
Location: Four Seasons Hotel, Chicago
Presenters:

David Pernock, President and Chief Commercial Officer, and Pete Meyers, Chief Financial Officer

The presentations will be webcast live at the aforementioned times, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors + News Section.

On May 29, 2018 Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reported that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 12:00pm PST / 3:00pm EST. Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems, will be presenting and meeting with investors (Press release, Delcath Systems, MAY 29, 2018, View Source;p=RssLanding&cat=news&id=2351038 [SID1234527071]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Simpson’s presentation will be webcast live on the internet and can be accessed by visiting the News and Events section of the Company’s website at www.delcath.com. Following the presentation, a replay of the webcast will be archived on Delcath’s website for a period of time.

The conference will be held at the Luxe Sunset Bel Air Hotel, will feature 230 companies in the small-cap/micro-cap space, and will be attended by over 1,000 individuals.

On May 29, 2018 BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, reported the appointment of Özlem Türeci, M.D., as Chief Medical Officer, effective June 1, 2018 (Press release, BioNTech, MAY 29, 2018, View Source [SID1234527060]). Dr. Türeci has chaired BioNTech´s Scientific and Clinical Advisory Board since the inception of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted that Özlem has joined BioNTech as Chief Medical Officer," said Helmut Jeggle, Chairman of BioNTech. "She has an exceptional track record both as a physician scientist and as an entrepreneur and brings invaluable expertise to BioNTech."

Dr. Türeci has over 25 years of experience in cancer research and immuno-oncology, specifically in the identification of immunotherapeutic drug targets and the development of antibodies, as well as vaccinebased therapies. In 2001, Dr. Türeci co-founded Ganymed Pharmaceuticals as Chief Scientific Officer and became its Chief Executive Officer in 2008. Ganymed Pharmaceuticals, which focused on developing a new generation of first-in-class antibodies in solid cancers, was sold to Astellas Pharma, Inc. for EUR 422 million in 2016. Dr. Türeci is chairman and co-initiator of Ci3, the German Cluster Initiative of Individualized ImmunIntervention (Ci3) e.V., based in Mainz, Germany. She is also an executive board member of the Association for Cancer Immunotherapy (CIMT) (Free CIMT Whitepaper). She authored over 110 peer-reviewed publications and is an inventor on more than 80 patents and patent applications.

"I very much look forward to working with the team at BioNTech," commented Dr. Türeci. "The Company has an incredibly strong foundation in the science of immunotherapy, and I am excited to help lead its efforts to develop individualized treatments for patients with cancer and other critical diseases."

"BioNTech has grown significantly since its foundation in 2008 and has matured to a clinical-stage company with encouraging early clinical results," added Prof. Ugur Sahin, co-founder and CEO of BioNTech. "As we move forward with more advanced clinical studies in patients, we need a leader with significant experience in translational and advanced clinical development to complement our existing expertise. The appointment of Özlem will allow us to further broaden and accelerate our development activities."

On May 29, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, reported that management will present company overviews at the following conferences (Press release, Alnylam, MAY 29, 2018, View Source [SID1234527057]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bernstein 34th Annual Strategic Decisions Conference onFriday, June 1, 2018 at 9:00 am ET at the Grand Hyatt in New York City
Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018 at 4:00 pm ET at the Grand Hyatt in New York City
Goldman Sachs 39th Annual Global Healthcare Conference onThursday, June 14, 2018 at 9:20 am PT (12:20 pm ET) at the Terranea Resort in Rancho Palos Verdes, California

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.

On may 29, 2018 Alkermes plc (Nasdaq: ALKS) reported that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET (6:30 p.m. BST) from New York (Press release, Alkermes, MAY 29, 2018, View Source;p=RssLanding&cat=news&id=2351100 [SID1234527056]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Contact:
Jennifer Zibuda
Investor Relations
+1 781 609 6129